Alyssa Capel, Author at Rheumatology Advisor

Response to Secukinumab Shows Variations Across Psoriatic Arthritis Clusters

By

Alyssa Capel

October 27, 2020

Researchers compared the effect of secukinumab on the quality of life of patients with very early and established psoriatic arthritis.

Rheumatoid Arthritis

Treatment With DMARDs Improves Cardiovascular Abnormalities in Early Rheumatoid Arthritis

By

Alyssa Capel

October 13, 2020

Researchers determined the effect of disease-modifying antirheumatic drug therapy on patients with early rheumatoid arthritis with cardiovascular disease.

Ischemic stroke is the most common severe neurologic complication of APS. Among 1000 people with APS participating in the Euro-Phospholipid Project, 20% presented with stroke and 11% presented with transient ischemic stroke.2,5 About 13% of patients with stroke are aPL-positive,2 and they are more likely to be younger or female compared with aPL-negative patients.3 More than 20% of strokes in patients <45 years may be related to APS.3 In APS, stroke occurs when a clot forms in an arterial vessel of the brain or when clot or plaque debris travels from another site (usually the heart) to a blood vessel in the brain.2,3 Less common cerebrovascular diseases seen in patients with APS that may increase stroke risk are cerebral venous thrombosis, reversible cerebral vasoconstriction syndrome, acute ischemic encephalopathy (a rare feature of SLE), and Sneddon syndrome.3 To reduce stroke risk, clinicians may want to discuss modifiable risk factors for vascular disease, such as smoking and obesity, with those who are positive for aPL.3 Image Credit: Zephyr/Science Source

Scleroderma

Similar Outcomes for Ischemic Stroke Hospitalizations With and Without Systemic Sclerosis

By

Alyssa Capel

September 29, 2020

Researchers compared the hospitalization outcomes of patients with ischemic stroke with and without a secondary diagnosis of systemic sclerosis.

Spondyloarthritis

Interchangeability Observed Between 2 Measures of Minimal Disease Activity in Psoriatic Arthritis

By

Alyssa Capel

September 25, 2020

Researchers assessed the interchangeability of 2 measures of minimal disease activity in psoriatic arthritis.

Gout

Acute Gout Prophylaxis Not Associated With Lower Gout Flare Risk After XOI Therapy

By

Alyssa Capel

September 23, 2020

Researchers determined the real-world incidence of acute gout prophylaxis (AGP) while prescribing a xanthine oxidase inhibitor, and described the characteristics of AGP prescribing in reducing gout flares.

Rheumatoid Arthritis

Assessing Rates and Risk Factors for Interstitial Lung Disease in Patients With Rheumatoid Arthritis

By

Alyssa Capel

September 17, 2020

Researchers investigated the incidence rates of interstitial lung disease in patients with rheumatoid arthritis receiving tofacitinib and identified potential risk factors.

Spondyloarthritis

Anti-CD74 Antibodies Identified as Promising Tool to Support Diagnosis of Axial Spondyloarthritis

By

Alyssa Capel

September 3, 2020

Researchers evaluated the role of anti-CD74 antibodies in the diagnosis of axial spondyloarthritis and their association with disease duration and activity.

Scleroderma

Systemic Sclerosis Mortality Data Reveals Trends Over 48 Years

By

Alyssa Capel

September 2, 2020

Researchers identified secular trends associated with systemic sclerosis mortality over 48 years.

Gout

Febuxostat Not Associated With Increased Risks for CVD Events, All-Cause Mortality in Gout

By

Alyssa Capel

September 1, 2020

Researchers assessed whether febuxostat increased the risk of developing cardiovascular events, death from cardiac-cause, and all-cause mortalities.

A flare-up of psoriasis on a man's hands

Spondyloarthritis

Methotrexate Superior to Sulfasalazine as First-Line csDMARD Monotherapy in Patients With PsA

By

Alyssa Capel

September 1, 2020

Researchers evaluated drug retention and predictors for drug retention among patients with psoriatic arthritis receiving first-line conventional synthetic DMARD monotherapy.

Alyssa Capel

All articles by Alyssa Capel

Response to Secukinumab Shows Variations Across Psoriatic Arthritis Clusters

Treatment With DMARDs Improves Cardiovascular Abnormalities in Early Rheumatoid Arthritis

Similar Outcomes for Ischemic Stroke Hospitalizations With and Without Systemic Sclerosis

Interchangeability Observed Between 2 Measures of Minimal Disease Activity in Psoriatic Arthritis

Acute Gout Prophylaxis Not Associated With Lower Gout Flare Risk After XOI Therapy

Assessing Rates and Risk Factors for Interstitial Lung Disease in Patients With Rheumatoid Arthritis

Anti-CD74 Antibodies Identified as Promising Tool to Support Diagnosis of Axial Spondyloarthritis

Systemic Sclerosis Mortality Data Reveals Trends Over 48 Years

Febuxostat Not Associated With Increased Risks for CVD Events, All-Cause Mortality in Gout

Methotrexate Superior to Sulfasalazine as First-Line csDMARD Monotherapy in Patients With PsA

Upadacitinib Application for Ankylosing Spondylitis Submitted for Review